BCIC Ecology | Oncolytic Virus First Stock: Innovative Award Winning Project ImmVira Submits IPO
On June 25, 2025, Innovent, a clinical stage biotechnology company specializing in next-generation oncolytic immunotherapy, officially submitted its application for listing on the main board of the Hong Kong Stock Exchange, with Citibank and CICC serving as joint sponsors. This move marks the beginning of a new chapter in the capital market for this innovative pharmaceutical company, founded by a team of top international scientists and at the forefront of the global oncolytic virus field.
Yinuo Microelectronics was founded in 2015 by six authoritative scientists, including Professor Bernard Roizman, known as the “father of herpesviruses” (the inventor of the FDA’s first approved oncolytic virus product Imlygic/T-vec skeleton), and Dr. Zhou Guoying, the international inventor of targeted herpesviruses. The company has gathered top-notch wisdom in the field of virology and laid a solid technological foundation.
ImmVira has won the third prize in the BCIC 2024 Biomedical Innovation Competition. For more details, please refer to the BCIC official website（ https://bcicglobal.org/2024-biomedical-pitch-competition-winners/ ）